Cocrystal Pharma, Inc. develops antiviral therapeutics using a proprietary structure-based drug discovery platform. News for COCP centers on CDI-988, an oral direct-acting protease inhibitor for norovirus infection, including clinical-study updates, FDA Fast Track designation and scientific presentations on its 3CL protease mechanism.
Company updates also cover financial results, financing activity, NIH-supported influenza A/B polymerase research, and broader pipeline references to respiratory viruses and coronaviruses.
Cocrystal Pharma (Nasdaq: COCP) presented Phase 1 data for CDI-988, their lead pan-viral protease inhibitor and potential first oral antiviral for norovirus infection, at the 9th International Calicivirus Conference. The presentation highlighted CDI-988's favorable safety profile in human intestinal tissue and broad-spectrum antiviral activity against multiple norovirus genogroups.
The company recently received FDA clearance for its Investigation New Drug (IND) application to proceed with a Phase 1b human challenge study, expected to begin before year-end. The drug, developed using Cocrystal's proprietary structure-based platform technology, targets a highly conserved region in the active site of noroviruses and showed no serious adverse events in Phase 1 trials.
Cocrystal Pharma (Nasdaq: COCP) has received FDA clearance to proceed with a Phase 1b challenge study for CDI-988, their novel oral broad-spectrum protease inhibitor targeting norovirus infections. The study is expected to begin by year-end 2025.
CDI-988 represents a potential breakthrough as the first antiviral drug candidate for norovirus prevention and treatment, with no currently approved vaccines or therapeutics available. The drug has demonstrated broad-spectrum antiviral activity against major norovirus proteases including GII.4 and GII.17, and showed favorable safety in Phase 1 studies.
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CFO and co-CEO James Martin will deliver a company overview presentation on September 9, 2025 at 12:00 p.m. Eastern time.
The event will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. Martin will be available for one-on-one meetings with institutional investors and industry professionals throughout the conference. The presentation materials are accessible on the company's website.
Cocrystal Pharma (Nasdaq: COCP) reported Q2 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate CDI-988 showed favorable Phase 1 safety and tolerability results for norovirus treatment. A Phase 1b norovirus challenge study is planned for later in 2025.
Financial highlights include Q2 2025 net loss of $2.1 million ($0.20 per share), reduced from $5.3 million in Q2 2024. R&D expenses decreased to $1.1 million from $4.3 million year-over-year. The company reported $4.8 million in cash as of June 30, 2025.
CDI-988 demonstrated broad-spectrum activity against norovirus strains, including the prevalent GII.17 strains responsible for 2024-2025 outbreaks. The company's pipeline also includes CC-42344 for influenza treatment, which showed activity against highly pathogenic H5N1 avian influenza strains.
Cocrystal Pharma (Nasdaq: COCP) presented favorable Phase 1 results for its oral pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium. The study demonstrated that all doses (100 mg to 1200 mg) were well-tolerated, with lower treatment-emergent adverse events in CDI-988 subjects compared to placebo groups.
Key findings include: 28% adverse events in SAD cohorts (vs. 40% placebo) and 53% in MAD cohorts (vs. 92% placebo). No severe adverse events or significant ECG changes were reported. The company plans to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected subjects later this year, addressing an unmet medical need as there are currently no approved treatments or vaccines for norovirus.
Cocrystal Pharma (Nasdaq: COCP) announced that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for oral presentation at the 9th International Calicivirus Conference in September 2025. The presentation will showcase Phase 1 study results of CDI-988, designed as a treatment for norovirus infections.
CDI-988 was developed using Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor targeting 3CL viral proteases. The company has completed a Phase 1 randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The drug aims to address norovirus infections, which cause severe gastrointestinal illness with an estimated global societal cost of $60 billion annually.
Cocrystal Pharma (NASDAQ: COCP) has announced its participation in the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 12:00 p.m. Eastern time.
The event will feature a live Q&A session, and qualified investors can request one-on-one meetings with management through the conference platform. A video webcast of the presentation will be available within 48 hours on both the Cocrystal website and Channelchek, where it will remain accessible for 90 days.